Effects of low-molecular-weight heparin on platelets as compared with commercial heparin.
Five subjects were injected with 5,000 IU of commercial heparin and low-molecular-weight heparin at an interval of 20 days after each injection. Both heparins produced the same platelet factor 4 release immediately after administration (commercial heparin 114.6 +/- 21.6 ng/ml, low-molecular-weight heparin 113.1 +/- 22.1 ng/ml). However, commercial heparin induced a more evident potentiating effect on ADP-induced platelet aggregation and was still present 60 min after injection. Low-molecular-weight heparin had a higher anti-Xa-specific activity than that determined by activated partial thromboplastin time. The opposite was true for the commercial preparation.
D000244:Adenosine Diphosphate / Q000494:pharmacology; D001792:Blood Platelets / Q000187:drug effects*; D005170:Factor X / Q000037:antagonists & inhibitors; D015951:Factor Xa; D006493:Heparin / Q000494:pharmacology*; D006801:Humans; D008970:Molecular Weight; D010314:Partial Thromboplastin Time; D010974:Platelet Aggregation / Q000187:drug effects; D010978:Platelet Factor 4 / Q000096:biosynthesis
D010978:Platelet Factor 4; D000244:Adenosine Diphosphate; D005170:Factor X; D006493:Heparin; D015951:Factor Xa